Table 3

Analysis of TP53 mutations in DLBCL samples treated with low-dose radiotherapy

DLBCL samples
TP53 mutation analysis from IARC
Conclusion
PatientResponseMutationNo. of tumors with the mutationTransactivation classStructure-based predictionPredicted TP53 function
Resp 46: TCCser -TTCphe Functional NA Functional 
Resp 55: ACTthr -ATTile Functional NA Functional 
Resp — NA NA NA Functional 
Resp 92: CCCpro -CTCleu Complex NA Functional 
Resp — NA NA NA Functional 
Resp — NA NA NA Functional 
Resp 193: CAThis -CGTarg 61 Nonfunctional Nonfunctional Nonfunctional 
Resp — NA NA NA Functional 
Resp 142: CCTpro -TCTser Complex Functional Functional 
  223: CCTpro -CTTleu Complex Functional Functional 
  293: GGGgly -GAGglu Functional NA Functional 
10 Non 135: TGCcys -TACtyr 63 Nonfunctional Nonfunctional Nonfunctional 
11 Non 165: CAGglu -TAGstop 38 No data No data Nonfunctional 
12 Non 285: GAGglu -AAGlys 139 Nonfunctional Nonfunctional Nonfunctional 
DLBCL samples
TP53 mutation analysis from IARC
Conclusion
PatientResponseMutationNo. of tumors with the mutationTransactivation classStructure-based predictionPredicted TP53 function
Resp 46: TCCser -TTCphe Functional NA Functional 
Resp 55: ACTthr -ATTile Functional NA Functional 
Resp — NA NA NA Functional 
Resp 92: CCCpro -CTCleu Complex NA Functional 
Resp — NA NA NA Functional 
Resp — NA NA NA Functional 
Resp 193: CAThis -CGTarg 61 Nonfunctional Nonfunctional Nonfunctional 
Resp — NA NA NA Functional 
Resp 142: CCTpro -TCTser Complex Functional Functional 
  223: CCTpro -CTTleu Complex Functional Functional 
  293: GGGgly -GAGglu Functional NA Functional 
10 Non 135: TGCcys -TACtyr 63 Nonfunctional Nonfunctional Nonfunctional 
11 Non 165: CAGglu -TAGstop 38 No data No data Nonfunctional 
12 Non 285: GAGglu -AAGlys 139 Nonfunctional Nonfunctional Nonfunctional 

Samples from 12 DLBCL patients treated with low-dose radiotherapy (2 × 2 Gy) for various palliative reasons were screened for TP53 gene mutations. Nine patients responded partially or completely to the treatment (Resp). Three patients had a stable or progressive disease (Non). Nonsilent mutations are shown in the table. Predicted structural and functional characteristics of the mutations were obtained from the mutation validation tool of the IARC TP53 Mutation Database.

NA indicates not applicable; —, no mutation.

or Create an Account

Close Modal
Close Modal